Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Matt Downs"'
Autor:
Paige Colley, Karen Schouten, Nicole Chabot, Matt Downs, Lauren Anstey, Marc S. Moulin, Ruth E. Martin
Publikováno v:
International Review of Research in Open and Distributed Learning, Vol 20, Iss 3 (2019)
Approximately one in 10 employed Canadians worked in health care and social services in 2016. Health professionals perceive life-long learning as an important element of professional life and value flexibility in their continuing education activities
Externí odkaz:
https://doaj.org/article/7914268fe8f94c4793aadcf6cbed50a1
Autor:
Carryn M. Anderson, Christopher M. Lee, Deborah Saunders, Amarinthia E. Curtis, Neal E. Dunlap, Chaitali Nangia, Arielle S. Lee, Philip Kovoor, Voichita Bar-Ad, Abhinand V. Pedadda, Jon Holmlund, Matt Downs, Stephen T. Sonis
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:416-421
Avasopasem manganese (GC4419), an investigational selective dismutase mimetic radioprotector, reduced duration, incidence, and severity of severe oral mucositis (World Health Organization grade 3-4) in a phase 2b, randomized, double-blind trial of pa
Autor:
Tran M. Nguyen, Matt Downs, Neil Bennett, Vitaliy Matyushenko, Harumasa Nakamura, Damjan Osredkar, Shiwen Wu, Nathalie Goemans, Anna Ambrosini, Rahsa El Sherifc, Craig Campbell
Publikováno v:
Journal of Rare Diseases Research & Treatment. 7:5-15
Background: TREAT-NMD is a global neuromuscular (NM) organization, created to enhance infrastructure to facilitate novel therapeutics reaching patients. One main activity is aimed at supporting NM disease registries. These rare disease registries are
Publikováno v:
Chest. 162:A2254
Autor:
Jon Holmlund, Jeffrey Mark Brill, Christopher M. Lee, Deborah Saunders, Stephen T. Sonis, Matt Downs, Carryn M. Anderson
Publikováno v:
Journal of Clinical Oncology. 37:TPS6096-TPS6096
TPS6096 Background: Approximately 70% of patients receiving intensity-modulated radiotherapy (IMRT) plus cisplatin for locally advanced head and neck cancer (HNC) develop SOM, defined as WHO Grade 3 or 4, which limits patients' ability to eat solids